Neurim Pharmaceuticals

Company Overview

Snapshot

Founded in June 1991 by Nava Zisapel, Neurim Pharmaceuticals operates with 11–50 employees. The company has secured funding across one round from Prof. Nava & Yehuda Zisapel. In September 2025, Health Canada granted marketing authorization for Slenyto®, an extended-release melatonin formulation, as a prescription drug for insomnia in children with Autism Spectrum Disorder and Smith-Magenis Syndrome.

Business overview

Neurim Pharmaceuticals is a drug discovery and development company focused on creating new chemical entities for brain restoration and ongoing support. The company's product portfolio addresses insomnia, central nervous system problems, and neurodegenerative diseases. Its flagship products include Circadin, a timed-release melatonin for insomnia, and Slenyto, a pediatric prolonged-release melatonin for children and adolescents with autism spectrum disorder and/or Smith-Magenis syndrome who suffer from insomnia. Neurim Pharmaceuticals serves markets in Europe, the Asia-Pacific region, and the Middle East, operating within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals and Drugs Discovery & Development.

Strategic signal

In September 2025, Neurim Pharmaceuticals received marketing authorization from Health Canada for Slenyto®, an extended-release melatonin formulation, for the treatment of insomnia in children with Autism Spectrum Disorder and Smith-Magenis Syndrome. This approval signifies a significant regulatory and commercial milestone, validating the company's research and development efforts in pediatric neurodevelopmental disorders and opening a new market for its specialized therapeutic solutions.

Company Intelligence Q&A

What was a significant regulatory approval for Neurim Pharmaceuticals?

In September 2025, Health Canada granted marketing authorization for Slenyto®, an extended-release melatonin formulation, as a prescription drug for insomnia in children with autism spectrum disorder and Smith-Magenis syndrome.

Which product did Neurim Pharmaceuticals grant marketing rights for in Spain?

In March 2017, Neurim Pharmaceuticals granted Exeltis marketing rights for Paediatric Prolonged-Release Melatonin (PedPRM) in Spain.

What was the outcome of an Alzheimer's disease trial reported by Neurim Pharmaceuticals?

In June 2014, Neurim Pharmaceuticals reported success in an Alzheimer's disease trial.

What positive opinion did Neurim Pharmaceuticals receive for Slenyto?

In July 2018, Neurim Pharmaceuticals received a positive CHMP opinion for Slenyto (Pediatric Prolonged-Release Melatonin) for the treatment of insomnia in children with Autism Spectrum Disorder (ASD).

When was Neurim Pharmaceuticals founded and by whom?

Neurim Pharmaceuticals was founded in June 1991 by Nava Zisapel.